Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Ozanimod: a better or just another S1P receptor modulator?
Endocannabinoids and Endocannabinoid-Related Mediators: Targets, Metabolism and Role In Neurological Disorders.
Gait variability in people with neurological disorders: A systematic review and meta-analysis.
Spatial modeling of multiple sclerosis for disease subtype prediction.
Reassessment of Lhermitte's sign in multiple sclerosis.
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders.
Newer multiple sclerosis drugs and disability scores - are key data analyses missing?
Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy.
Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
[Multiple sclerosis: new drugs and their molecular targets].
Cognitive Impairments in Multiple SclerosisImplications for Rehabilitation.
Calcium intervention ameliorates experimental model of multiple sclerosis.
Brain glycolipids suppress T helper cells and inhibit autoimmune demyelination.
Biomarkers of interferon Beta therapy in multiple sclerosis.
Chronic cerebrospinal venous insufficiency is not more prevalent in patients with mild multiple sclerosis: a sonographer-blinded, case-control ultrasound study.
Which is the goal of cognitive rehabilitation in multiple sclerosis: the improvement of cognitive performance or the perception of cognitive deficits?
Growth Hormone and Disease Severity in Early Stage of Multiple Sclerosis.
The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases.
Therapeutic Effect of Transplanted Human Wharton's Jelly Stem Cell-Derived Oligodendrocyte Progenitor Cells (hWJ-MSC-derived OPCs) in an Animal Model of Multiple Sclerosis.
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy.
Intravenous immunoglobulin preparation attenuates neurological signs in rat experimental autoimmune neuritis with the suppression of macrophage inflammatory protein -1α expression.
The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper.
Effects of dextromethorphan on glial cell function: Proliferation, maturation, and protection from cytotoxic molecules.
How embodied is action language? Neurological evidence from motor diseases.
Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
Pages
« first
‹ previous
…
504
505
506
507
508
509
510
511
512
…
next ›
last »